599183-36-5

Basic information

• Product Name: 5-AMINO-3-IODO (1H)INDAZOLE
• Synonyms: 5-AMINO-3-IODO (1H)INDAZOLE;5-AMINO-3-IODOINDAZOLE;5-Amino-3-iodo-1H-indazol...;3-Iodo-1H-indazol-5-aMine;3-Iodo-1H-indazol-5-ylaMine
• CAS NO: 599183-36-5
• Molecular Formula: C₇H₆IN₃
• Molecular Weight: 259.05
• Mol File: 599183-36-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 5-AMINO-3-IODO (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-3-IODO (1H)INDAZOLE(599183-36-5)
• EPA Substance Registry System: 5-AMINO-3-IODO (1H)INDAZOLE(599183-36-5)

Safety Data

• Hazardous Substances Data: 599183-36-5(Hazardous Substances Data)

Usage

General Description

5-Amino-3-iodo (1H)indazole, also known as 3-iodo-5-aminoindazole, is a chemical compound with a molecular formula C7H6IN3. It is a derivative of indazole, a heterocyclic aromatic organic compound. 5-Amino-3-iodo (1H)indazole is commonly used as a building block in organic synthesis and pharmaceutical research, particularly in the development of potential drug candidates. Its unique structure and properties make it a valuable intermediate for the synthesis of various pharmacologically active compounds. As a result, 5-Amino-3-iodo (1H)indazole has garnered significant interest in medicinal chemistry and drug discovery efforts, with potential applications in the development of novel therapeutic agents.

Upstream product

• 70315-69-4 3-iodo-5-nitro-1H-indazole 
• 5401-94-5 5-nitroindazole 
• 917474-59-0 (1H-indazol-5-yl)-carbamic acid tert-butyl ester 
• 1338795-64-4 tert-butyl (3-iodo-1H-indazol-5-yl)carbamate 

Relevant articles and documents

Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design

Aurora kinases have emerged as important anticancer targets so that there are several inhibitors have advanced into clinical study. Herein, we identified novel indazole derivatives as potent Aurora kinases inhibitors by utilizing in silico fragment-based approach and knowledge-based drug design. After intensive hit-to-lead optimization, compounds 17 (dual Aurora A and B), 21 (Aurora B selective) and 30 (Aurora A selective) possessed indazole privileged scaffold with different substituents, which provide sub-type kinase selectivity. Computational modeling helps in understanding that the isoform selectivity could be targeted specific residue in the Aurora kinase binding pocket in particular targeting residues Arg220, Thr217 or Glu177.

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization

We describe structure-based optimization of a series of novel 2,4-diaminopyrimidine MK2 inhibitors. Co-crystal structures (see accompanying Letter) demonstrated a unique inhibitor binding mode. Resulting inhibitors had IC50 values as low as 19 nM and moderate selectivity against a kinase panel. Compounds 15, 31a, and 31b inhibit TNFα production in peripheral human monocytes.